Hal Barron, GSK R&D chief (UKBIO19)
July 27, 2022 10:13 AM EDT
R&D

Hal Bar­ron’s swan song at GSK: An ‘ex­cep­tion­al’ lega­cy, thoughts on risk and a sin­gu­lar de­ci­sion-mak­ing mod­el

John Carroll

Editor & Founder

With boom­ing Shin­grix sales fill­ing its fi­nan­cial sails in the wake of the Ha­le­on spin­out, the ex­ec­u­tive team at New GSK re­peat­ed­ly tout­ed the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

A service from the Financial Times